HK1257648A1 - Fxr促效劑之使用方法 - Google Patents
Fxr促效劑之使用方法Info
- Publication number
- HK1257648A1 HK1257648A1 HK19100006.1A HK19100006A HK1257648A1 HK 1257648 A1 HK1257648 A1 HK 1257648A1 HK 19100006 A HK19100006 A HK 19100006A HK 1257648 A1 HK1257648 A1 HK 1257648A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- methods
- fxr agonists
- fxr
- agonists
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662298117P | 2016-02-22 | 2016-02-22 | |
| US201662420702P | 2016-11-11 | 2016-11-11 | |
| PCT/IB2017/050912 WO2017145031A1 (en) | 2016-02-22 | 2017-02-17 | Methods for using fxr agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1257648A1 true HK1257648A1 (zh) | 2019-10-25 |
Family
ID=58191506
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK19100006.1A HK1257648A1 (zh) | 2016-02-22 | 2019-01-02 | Fxr促效劑之使用方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11229634B2 (zh) |
| EP (1) | EP3419623B1 (zh) |
| JP (1) | JP7053478B2 (zh) |
| KR (1) | KR20180116275A (zh) |
| CN (2) | CN108697704A (zh) |
| AU (1) | AU2017223148B2 (zh) |
| CA (1) | CA3014731A1 (zh) |
| ES (1) | ES2902404T3 (zh) |
| HK (1) | HK1257648A1 (zh) |
| IL (1) | IL261021A (zh) |
| RU (1) | RU2018133157A (zh) |
| TW (1) | TW201735923A (zh) |
| WO (1) | WO2017145031A1 (zh) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2878575T3 (es) | 2016-02-22 | 2021-11-19 | Novartis Ag | Métodos para usar agonistas del FXR |
| AU2017223148B2 (en) | 2016-02-22 | 2019-07-18 | Novartis Ag | Methods for using FXR agonists |
| PT3419624T (pt) | 2016-02-22 | 2021-04-07 | Novartis Ag | Métodos para utilizar agonistas de fxr |
| AR114930A1 (es) | 2017-09-12 | 2020-11-11 | Novartis Ag | Composición farmacéutica |
| TW201936189A (zh) * | 2017-11-30 | 2019-09-16 | 瑞士商諾華公司 | 用於使用fxr激動劑之方法 |
| CN111263759B (zh) | 2017-12-22 | 2023-03-28 | 四川科伦博泰生物医药股份有限公司 | 异噁唑衍生物及其制备方法和用途 |
| KR20220035365A (ko) | 2019-07-18 | 2022-03-22 | 엔요 파마 | 인터페론의 부작용을 감소시키는 방법 |
| WO2021144330A1 (en) | 2020-01-15 | 2021-07-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of fxr agonists for treating an infection by hepatitis d virus |
| EP4277622A1 (en) | 2021-01-14 | 2023-11-22 | ENYO Pharma | Synergistic effect of a fxr agonist and ifn for the treatment of hbv infection |
| TW202308629A (zh) | 2021-04-28 | 2023-03-01 | 法商Ｅｎｙｏ製藥公司 | 使用fxr激動劑作為組合治療以增強tlr3激動劑之療效 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9601091L (sv) | 1996-03-21 | 1997-09-22 | Joyce Carlson | Användning av en proteinsubstans för bindning av steroid-liknande molekyler |
| EP2173174A4 (en) | 2007-07-02 | 2010-08-04 | Glaxosmithkline Llc | FARNESOID X RECEPTOR AGONISTS |
| DK2219652T3 (da) | 2007-11-16 | 2012-08-06 | Baylor College Medicine | Phospholipidsammensætninger og anvendelser heraf |
| CU24152B1 (es) | 2010-12-20 | 2016-02-29 | Irm Llc | 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr |
| AU2017223148B2 (en) | 2016-02-22 | 2019-07-18 | Novartis Ag | Methods for using FXR agonists |
| PT3419624T (pt) | 2016-02-22 | 2021-04-07 | Novartis Ag | Métodos para utilizar agonistas de fxr |
-
2017
- 2017-02-17 AU AU2017223148A patent/AU2017223148B2/en not_active Ceased
- 2017-02-17 JP JP2018544176A patent/JP7053478B2/ja active Active
- 2017-02-17 ES ES17707959T patent/ES2902404T3/es active Active
- 2017-02-17 CN CN201780012841.6A patent/CN108697704A/zh active Pending
- 2017-02-17 CN CN202111201913.6A patent/CN113908158A/zh active Pending
- 2017-02-17 RU RU2018133157A patent/RU2018133157A/ru unknown
- 2017-02-17 WO PCT/IB2017/050912 patent/WO2017145031A1/en active Application Filing
- 2017-02-17 US US16/078,403 patent/US11229634B2/en active Active
- 2017-02-17 EP EP17707959.7A patent/EP3419623B1/en active Active
- 2017-02-17 CA CA3014731A patent/CA3014731A1/en not_active Abandoned
- 2017-02-17 KR KR1020187023974A patent/KR20180116275A/ko unknown
- 2017-02-22 TW TW106105847A patent/TW201735923A/zh unknown
-
2018
- 2018-08-07 IL IL261021A patent/IL261021A/en unknown
-
2019
- 2019-01-02 HK HK19100006.1A patent/HK1257648A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017223148A1 (en) | 2018-08-30 |
| JP7053478B2 (ja) | 2022-04-12 |
| TW201735923A (zh) | 2017-10-16 |
| CN113908158A (zh) | 2022-01-11 |
| US11229634B2 (en) | 2022-01-25 |
| ES2902404T3 (es) | 2022-03-28 |
| EP3419623B1 (en) | 2021-09-29 |
| KR20180116275A (ko) | 2018-10-24 |
| AU2017223148B2 (en) | 2019-07-18 |
| RU2018133157A (ru) | 2020-03-24 |
| RU2018133157A3 (zh) | 2020-05-29 |
| IL261021A (en) | 2018-10-31 |
| EP3419623A1 (en) | 2019-01-02 |
| JP2019509278A (ja) | 2019-04-04 |
| WO2017145031A1 (en) | 2017-08-31 |
| CA3014731A1 (en) | 2017-08-31 |
| CN108697704A (zh) | 2018-10-23 |
| US20190046518A1 (en) | 2019-02-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1257647A1 (zh) | 使用fxr促效劑之方法 | |
| HK1257649A1 (zh) | 使用fxr激動劑的方法 | |
| ZA201805680B (en) | Methods for making l-glufosinate | |
| HK1257648A1 (zh) | Fxr促效劑之使用方法 | |
| EP3116878A4 (en) | Fxr agonists and methods for making and using | |
| GB201402343D0 (en) | Method for identifying anomalies | |
| SG11201702568QA (en) | Holder for objects | |
| HUE045962T2 (hu) | Magmintatartó | |
| IL246889A0 (en) | A method for measuring engagement | |
| SG11201607851PA (en) | Method for analyzing mixture components | |
| GB2528376B (en) | Lubricant test method | |
| IL265139B (en) | Dopamine-b-hydroxylase inhibitors | |
| IL240359A0 (en) | Rigid sliding unit manufacturing method | |
| IL264628A (en) | Combination of fxr agonists | |
| HUE053440T2 (hu) | Embrió-mintavételezõ eljárás | |
| GB201612860D0 (en) | Inhibitors | |
| GB201400960D0 (en) | Sliding Sleeve Tool | |
| HK1224016A1 (zh) | 用於測定流體樣本的擴散 | |
| DK3189327T3 (en) | Ph-sensor for metaloxid | |
| GB201700439D0 (en) | Methods for assessing vaginal atrophy | |
| GB2524130B (en) | Analysing Apparatus | |
| EP3234547B8 (en) | Dual component density sampler apparatus | |
| FI3026555T3 (fi) | Menetelmä arkkitehtuurin hallinnoimiseksi ja siihen liittyvä arkkitehtuuri | |
| GB2534838B (en) | Sample holder | |
| GB201500297D0 (en) | Agonists |